Abstract
Crohn's disease and ulcerative colitis are idiopathic inflammatory bowel diseases characterized by dysregulated intestinal immune responses in genetically susceptible hosts. Conventional approaches to the medical therapy of ulcerative colitis and Crohn's disease can now be directed at either induction or maintenance of remission to improve therapeutic efficacy while minimizing complications. Newer approaches have expanded the utility of conventional therapies by improving both safety and efficacy and highlight the importance of specific targets along the immunoinflammatory pathways. The combination of conventional and novel approaches now offers the potential of modifying the natural history of these diseases.
Original language | English (US) |
---|---|
Pages (from-to) | 299-318 |
Number of pages | 20 |
Journal | Annual review of medicine |
Volume | 52 |
DOIs | |
State | Published - Mar 17 2001 |
Keywords
- Biologic therapies
- Crohn's disease
- Infliximab
- Ulcerative colitis
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)